Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print The effective chemoradiotherapy method for pancreatic cancer

The effective chemoradiotherapy method for pancreatic cancer

September 22, 2008

Pancreatic cancer is the fifth most common cause of cancer death in Japan. The prognosis is extremely poor because it is difficult to detect this disease in the early stage and also the postoperative incidence of recurrence is still high, and we have not had any effective treatment for inoperable patients. Recently, the chemoradiotherapy has been regarded as one of the standard therapy for locally advanced pancreatic cancer and it has improved the survival and presented a clinical benefit. In the early 1980s, fluorouracil-based concomitant chemoradiotherapy was shown to be better than radiotherapy alone for patients with locally advanced pancreatic cancer. Gemcitabine has improved the outcome of patients with advanced disease by improving survival with a clinical benefit. Gemcitabine also has been shown to be a potent radiosensitizer both in vivo and in vitro. The vast majority of the reported phase I-III clinical trials have used gemcitabine as a single agent given weekly in a single dose (i.e. 250 mg/m2), and there is no consensus of the protocol of the administration of gemcitabine. Several preclinical data including animal studies would suggest that maximum radiation sensitization with gemcitabine is observed at a lower dose administered twice weekly.

A research article to be published on September 14, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. IGARASHI from Pancreatic Diseases Branch of Kyushu University in Japan focused on the maximum radiation sensitization with gemcitabine. They performed the retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine at a dose of 1000 mg/m2 was administered weekly for 3 weeks with 1-week rest until disease progression or unacceptable toxicity. Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy, because one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis in an early stage of therapy. The median survival was 15.0 months and the overall 1-year survival rate was 60%, while the median progression- free survival was 8.0 months. The subgroup which showed the reduction of tumor maker more than 50%, had a tendency for a better prognosis, however other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 months and 27.7 months, respectively.




Although this study using a twice weekly gemcitabine infusion schedule for locally advanced pancreatic cancer was not a controlled study, the results of the median survival time, median disease free survival time and overall 1-year survival rate was found to be preferable compared to previous studies.

Hugut et al (J Clin Oncol 2007; 25: 326-331) discussed that, an important concern about administrating chemoradiotherapy as first-line treatment in patients with locally advanced pancreatic cancer was that approximately 30% of them had occult metastatic disease at diagnosis and thus they would clearly not benefit from this locoregional treatment. Furthermore, other investigator demonstrated that a fraction of patients with locally advanced pancreatic cancer developed metastases within a few weeks and died very quickly despite the type of treatment. In this study, the patients who developed liver metastasis had a worse prognosis, which might owe to the mis-diagnosis of the staging of the disease at the initiation of the therapy, because of failure to detect micrometastasis by conventional imaging modalities. In this situation, another strategy for the chemoradiotherapy for locally advanced pancreatic cancer might be required, such as one in which the patients receive one or two cycles of systemic chemotherapy using gemcitabine at a dose of 1,000 mg/m2 weekly for 3 weeks with 1-week rest, and then re-evaluated the staging of the disease, initiating the chemoradiotherapy under the protocol in this study. Further investigations are required in the near future.

World Journal of Gastroenterology



Related Pancreatic Cancer Current Events and Pancreatic Cancer News Articles Pancreatic Cancer Current Events and Pancreatic Cancer News RSS Pancreatic Cancer Current Events and Pancreatic Cancer News RSS
Rare pancreatic cancer patients may live longer when treated with radiation therapy
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy.

African-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.

Discovery offers potential new pancreatic cancer treatment
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.

M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

Endothelin-1 inhibitors in chronic pancreatitis
Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour.

Autoimmune response can induce pancreatic tumor rejection
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.

MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease.

Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series)

Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series)
by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor)

Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important...

100 Q&A About Pancreatic Cancer (100 Questions & Answers)

100 Q&A About Pancreatic Cancer (100 Questions & Answers)
by Joanne Frankel Kelvin Eileen O'Reilly (Author)

EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an...

100 Questions & Answers About Pancreatic Cancer, Second Edition

100 Questions & Answers About Pancreatic Cancer, Second Edition
by Eileen O'Reilly (Author), Joanne Frankel Kelvin (Author)

Whether you re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor s and patient s view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an invaluable...

My Journey With Pancreatic Cancer

My Journey With Pancreatic Cancer
by Calvin Rains (Author)

This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year.This book is intended to help the patient, their families, and friends to understand the dangers and possible treatments. It is vital that the patient and their families understand the importance of choices of treatment and the possible side effects.This is basically a diary of one patient who has been able to survive five (5) years at this writing. The road can be challenging, but healing is possible if discovered and treated quickly. This book will help the patient and their families to better deal with...

Clearly Charming Purple Ribbon Pancreatic Cancer, Fibromyalgia, Lupus Italian Charm

Clearly Charming Purple Ribbon Pancreatic Cancer, Fibromyalgia, Lupus Italian Charm
by Clearly Charming

Purple ribbon stands for domestic violence, pancreatic cancer, Chrons Disease and colitis, Cystic Fibrosis, Fibromyalgia, and Lupus awareness. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show off your birthstone by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet.

Cancer Be Gone

Cancer Be Gone

Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed".

Beating Pancreatic Cancer Together T-shirt Large White

Beating Pancreatic Cancer Together T-shirt Large White
by Shop Zeus



Pancreatic Cancer Awareness Ribbon Mouse Pad

Pancreatic Cancer Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Pancreatic Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pancreatic Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pancreatic Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

Pancreatic Cancer

Pancreatic Cancer
by Daniel D. Von Hoff (Editor) (Author)

Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and complete text on pancreatic cancer available.” -- John L. Cameron, MD The Alfred Blalock Distinguished Service Professor The Johns Hopkins University School of Medicine

Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps

Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps
by Maximum International

Having attracted worldwide interest as an inhibitor of malignant cell growth, this remarkable Amazonian herb has been studied in more than 20 laboratory tests for its anti-tumor and cell protective qualities. The best Graviola on the market. Maximum Int'l. is the company with the most potent products available. Lab tested to make sure the ingredients are of the most superior quality and highes quality raw materials available. This product is manufactured in an FDA inspected and GMP certified facility. Quality is guaranteed.

© 2009 BrightSurf.com